Comparisons

Compounded Tirzepatide vs Brand: Risks and Questions

GLP-1 Companion · 8 min read

When Mounjaro and Zepbound faced supply shortages between 2023 and 2024, compounding pharmacies stepped in to fill the gap. They produced tirzepatide-based injections at a fraction of the brand cost, and millions of patients turned to them. By early 2025, however, the FDA had declared the tirzepatide shortage resolved, and the regulatory landscape shifted dramatically. Understanding where things stand in 2026 is essential before considering compounded versions of this medication.

What Is Compounding and Why It Exists

Pharmaceutical compounding is the practice of preparing a custom medication for an individual patient when a commercially available product does not meet their needs. Licensed compounding pharmacies can legally produce medications for specific clinical needs — for example, a patient who is allergic to an inactive ingredient in a commercial drug. During a declared FDA drug shortage, compounders are also permitted under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act to produce copies of the shortage drug, including injectable peptides like tirzepatide.

The Tirzepatide Shortage and Its Resolution

The semaglutide shortage (affecting Ozempic and Wegovy) was more severe and persisted longer than the tirzepatide shortage. Eli Lilly scaled manufacturing faster than Novo Nordisk, and by October 2024 the FDA removed tirzepatide from its official drug shortage database. This is a critical legal distinction: once a drug shortage is resolved, the legal basis for 503A and 503B compounding of that drug disappears. The FDA issued guidance in late 2024 and reinforced enforcement in 2025 warning that compounded tirzepatide was no longer legally protected under shortage exemptions.

FDA Enforcement Actions and Warnings

The FDA has been active in warning consumers and taking action against pharmacies producing compounded GLP-1 medications. In 2024 and 2025, the agency issued multiple warning letters to compounders and sent import alerts targeting foreign-sourced peptides marketed as tirzepatide. The FDA specifically warned consumers that compounded tirzepatide products have not been proven safe or effective, and that several adverse event reports — including hospitalizations related to dosing errors — were linked to compounded products.

• FDA warning letters were sent to compounders citing violations of current Good Manufacturing Practice (cGMP) standards.
• Some compounded tirzepatide products were found to contain tirzepatide salts (such as acetate or trifluoroacetate forms) rather than the base peptide used in Zepbound and Mounjaro. These salt forms are not the same molecule and have not been tested for safety or efficacy in humans.
• Dosing errors due to ambiguous concentration labeling on compounded vials resulted in adverse event reports submitted to the FDA.
• The FDA does not inspect most 503A compounding pharmacies with the same frequency as commercial drug manufacturers.

Quality and Dosing Risks of Compounded Versions

Brand-name Zepbound and Mounjaro are manufactured in FDA-inspected facilities under strict cGMP requirements. Every batch is tested for potency, purity, sterility, and stability. Compounded products are not subject to the same oversight. Independent analyses of compounded GLP-1 products have found meaningful variability between the labeled dose and actual content. A vial labeled as 5 mg per mL may contain significantly more or less than that amount, which creates real risk — underdosing leads to poor outcomes while overdosing increases the risk of severe nausea, pancreatitis, and other adverse effects.

The Salt Form Problem

Many compounding pharmacies source raw tirzepatide from API (active pharmaceutical ingredient) suppliers, often overseas. A significant subset of these API sources provide tirzepatide in salt form, not the base peptide form used in the approved drugs. The FDA has explicitly stated that tirzepatide salts are different chemical entities from the active ingredient in Mounjaro and Zepbound. There is no clinical data demonstrating that these salt forms are bioequivalent, and they are not covered by any shortage-based exemption.

Legal Status in 2026

In 2026, compounded tirzepatide occupies contested legal territory. Large 503B outsourcing facilities had until March 2025 to cease production under FDA guidance, and the FDA pursued enforcement against those that continued. Individual 503A pharmacies may still legally compound tirzepatide for a specific patient if there is a documented clinical need that the commercial product cannot meet — for example, a patient requiring a dose not commercially available, or one with a documented allergy to an excipient in the commercial product. General sales of compounded tirzepatide to the public without individualized prescriptions for a specific need are not legally protected.

Why Patients Still Seek Compounded Versions

The core driver is cost. Brand-name Zepbound and Mounjaro carry list prices exceeding $1,000 per month without insurance. Even with the Lilly Savings Card, which can reduce costs to approximately $550 per month for eligible commercially insured patients, the out-of-pocket expense is significant. Compounded tirzepatide was widely available for $200 to $400 per month. For patients who cannot afford the brand medication, the financial logic is understandable — but the risks are real.

What To Do If Cost Is a Barrier

There are legitimate pathways to reduce the cost of brand-name tirzepatide that do not carry the safety risks of compounded versions. Exploring these options with your healthcare provider and a patient advocate is strongly recommended before turning to compounded alternatives.

1. Lilly Cares Foundation Patient Assistance Program: Patients with household incomes below 400% of the federal poverty level may qualify for free or significantly reduced-cost Zepbound or Mounjaro.
2. Lilly Savings Card: Commercially insured patients may pay as little as $25 to $550 per month depending on their plan and eligibility.
3. Formulary review with your insurer: Some plans cover Zepbound for obesity (BMI 30+ or BMI 27+ with comorbidity) or Mounjaro for type 2 diabetes. A prior authorization letter from your provider documenting medical necessity can improve coverage odds.
4. GoodRx and pharmacy discount programs: These do not typically make a large dent in brand GLP-1 costs but are worth checking.
5. Clinical trials: ClinicalTrials.gov lists ongoing studies with tirzepatide where participants may receive the medication at no cost.
6. Ask your provider about dose-splitting strategies: Some providers prescribe higher-dose pens and have patients split doses under close supervision, though this is off-label and requires careful guidance.

The Bottom Line

Compounded tirzepatide is no longer legally protected under the FDA shortage exemption, carries real risks of inconsistent potency and potentially different chemical forms, and has been linked to adverse events in safety reports. The FDA has been clear about its position. If you are currently using compounded tirzepatide, discuss the situation with your prescriber and explore whether brand-name access programs make the switch feasible. Your safety depends on knowing exactly what is in your injection.

The FDA has stated: "Compounded drugs are not FDA-approved. FDA does not evaluate them for safety, effectiveness, or quality before they are marketed." For a medication administered by injection where dosing precision matters, this distinction is clinically significant.

Sources

• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.
• Mounjaro (tirzepatide) Prescribing Information. Eli Lilly.